Please wait while the transcript is being prepared...
0:00
I'm Angela Cheung
from Toronto, Canada,
and I am going to discuss
Atypical Femoral Fractures today.
0:09
These are my disclosures.
I have received honoraria from,
for CME events and/or grants
to my institution from these companies.
And I've also been a member of
the ASBMR International Task Force
on Atypical Femoral Fractures,
as well as the Osteoporosis
Canada Guidelines
on the Diagnosis, Management,
and Prevention of
Atypical Femoral Fractures.
0:37
I'm going to discuss
the definition, epidemiology,
clinical risk factors,
diagnosis and management,
and prevention
of atypical femoral fractures.
0:49
Right now in osteoporosis,
these are the pharmacological therapies,
they are in Canada.
The first line therapies are
antiresorptive therapies
with bisphosphonates,
denosumab, raloxifene,
and estrogen in menopausal women
with symptoms
as well as bone formation therapy,
and we only have one,
it's called teriparatide.
These therapies have been shown
to reduce vertebral fracture,
hip fractures,
and non-vertebral fractures
as you can see on the slide
based on randomized control trials.
1:30
They've also been shown,
especially the antiresorptive therapies
with bisphosphonates and denosumab
in a meta-analysis done by Bolland,
they have been shown to reduce
mortality as well.
The relative risk here of 0.89
is statistically significant.
